Bone Mineral Density: Clinical Relevance and Quantitative Assessment

Area of Science:

• Endocrinology
• Geriatrics
• Radiology

Background:

• Bone mineral density (BMD) measurement via dual-energy x-ray absorptiometry (DXA) is the standard for assessing fragility fracture risk.
• Guidelines recommend DXA screening and the fracture risk assessment tool (FRAX) for managing osteoporosis treatment decisions.

Purpose of the Study:

• To outline current guidelines for osteoporosis screening and pharmacologic treatment.
• To discuss the role of BMD monitoring and treatment response.
• To address considerations for patients with inadequate treatment response or incident fractures.

Main Methods:

• Review of U.S. National Osteoporosis Foundation guidelines.
• Application of FRAX for treatment threshold determination.
• Serial DXA scans for monitoring treatment efficacy.
• Consideration of secondary osteoporosis causes and non-compliance.

Main Results:

• Pharmacologic treatment is warranted for postmenopausal women and men over 50 with osteopenic BMD if 10-y hip fracture probability is ≥3% or major osteoporotic fracture probability is ≥20% via FRAX.
• Patients with fragility fractures or osteoporotic BMD also require treatment.
• Monitoring BMD response to therapy is essential, though treatment cessation is complex due to reversibility and potential increased fracture risk (e.g., denosumab).

Conclusions:

• DXA and FRAX are key tools for osteoporosis management.
• Regular monitoring and assessment of treatment response are vital.
• Investigating secondary causes or non-compliance is necessary for patients not responding to therapy or experiencing fractures during treatment.